Stemedica a leading manufacturer of adult allogeneic stem cells and stem cell factors, announced today that the Company has been issued Patent No. US 8,642,286 B2 entitled, Methods for Identifying Neuripotent Cells by the United States Patent…
Stemedica a leading manufacturer of adult, allogeneic stem cells and stem cell factors, welcomes Byung-Geon “BG” Rhee, Ph.D., President of Green Cross Holdings, a South Korean biopharmaceutical company, to its board of directors. Green Cross,…
Stemedica announced today that Richard Mejia, Jr. has joined the Company’s Board of Directors and will be Chairman of the Company’s Audit Committee effective January 31, 2014. Mr. Mejia spent 38 years with Ernst & Young, LLP where he was a partner for 25 years. He…
Stemedica a leader in adult allogeneic stem cell manufacturing, research and development, announced today that Craig W. Carlson has been appointed the Company’s Chief Financial Officer effective March, 2014. Craig Carlson brings 34 years of…
Stemedica a leader in adult allogeneic stem cell manufacturing, research and development, announced today the completion of enrollment and treatment of patients in a Phase I study with Stemedica’s lead product Stemedyne-MSC. These specially…
Abstract The dependences of spreading and differentiation of stem cells plated on hydrogel and silicone gel substrates on the rigidity and porosity of the substrates have recently been a subject of some controversy. In experiments on human mesenchymal stem cells…
Stemedica a leader in adult allogeneic stem cell manufacturing, research and clinical development, announced today they have entered into a Global Distribution Agreement with Life Technologies Corporation. Under the terms of this agreement,…
Abstract Object. The multipotency of neural stem cells (NSCs) can be assessed in vitro by detection of stage-specific markers in response to a suitable differentiation signal. This test is frequently used because it is fast and affordable. However, it is not clear how…
Abstract Transplantation of human fetal neural stem cells (hNSCs) previously demonstrated significant functional recovery after spinal cord contusion in rats. Other studies indicated that human mesenchymal stem cells (hMSCs) can home to areas of damage and cross the…
Abstract Introduction A feature which makes stem cells promising candidates for cell therapy is their ability to migrate effectively into damaged or diseased tissues. Recent reports demonstrated the increased motility of human mesenchymal stem cells (hMSC) grown under…
Abstract Background context Spinal cord injury can lead to severe functional impairments secondary to axonal damage, neuronal loss, and demyelination. The injured spinal cord has limited regrowth of damaged axons. Treatment remains controversial, given inconsistent…
